讲座安排
?1. Cyber-medical system concept
? 时间： 2018 年 11 月 30 日，上午 ? ? ?10:00-11:30
地点：李兆基大楼 A744-2 会议室
?2. Artificial pancreas problem
? 时间： 2018 年 12 月 3 日，上午 ? ? ?10:00-11:30
地点：李兆基大楼 A409 会议室
?3. Tamed cancer concept
? 时间： 2018 年 12 月 4 日，上午 ? ? ?10:00-11:30
地点： 李兆基大楼 A409 会议室
? Abstract: ?By the needs of Industry 4.0 digitalization ? ?of industry has been accentuated.
However, cybersphysical ? ?systems left its footprints in healthcare as well, ? ?formalizing
the cyber-medical system requirements: how to help ? ?everyday life of medical doctors
and patients by using medical ? ?devices in a more personalized way. This concept meshes
the ? ?entire biomedical engineering research field. The idea is to create ? ?mathematical
algorithms able to be personalized on the ? ?patients’ need and physiology, use cloud
computation techniques ? ?to fasten the decision support and big data analysis for ? ?feature
extraction. As a result, the cyber-medical system ? ?concept is equivalent with a smart
healthcare framework where ? ?by using the computational power possibilities together
with ? ?machine learning, artificial intelligence and control engineering ? ?methods we
would like to intensify the decision support of ? ?doctors, nurses and patients in order to
use in an intelligent ? ?way the knowledge-based medical applications.
The 3x90 minutes ? ?lectures will give an overview on the above-mentioned aspects in ? ?the
following structure:
1. The cyber-medical system ? ?concept: what the trends are, how it is influencing ? ?our
everyday’s life including education, research, medical ? ?industry and healthcare sector.
Physiological modeling and ? ?control. Basics of modern robust control and LPV ? ?(Linear
Parameter Varying) modeling. The theoretical background ? ?will be exemplified by two
physiological / pathophysiological ? ?examples that are intensively researched nowadays:
diabetes and ? ?tumor control.
2. Artificial pancreas problem: Recent ? ?technological advances in diabetes treatment like
Continuous ? ?Glucose Monitors (CGMs) for the subcutaneous measurement of ? ?glucose
concentration and insulin pumps for the subcutaneous ? ?delivery of insulin allowed
investigating the applicability of ? ?an external controller. In type 1 diabetes, where the ?
?disease can be characterized as a general ? ?clinical picture (e.g. complete pancreatic β-
cell ? ?insufficiency) different individualized model-based (mostly model ? ?predictive
control (MPC) based) solutions have been already ? ?formulated and even clinical trials
appeared demonstrating its ? ?applicability. However, closing the loop needs the
integration ? ?of individualized control methods and robust control algorithms in ? ?order to
successfully reject hypoglycemic episodes. Moreover, ? ?the scientific community started
to transpose the problem on ? ?type 2 diabetes as well, trying to cover the largest ? ?diabetic
population with the artificial pancreas ? ?concept.
3. Tamed cancer concept: Beside general cancer ? ?therapies like chemotherapy, targeted
molecular therapies ? ?appeared in order to focus on a given mechanism of the ? ?tumor
growth stopping it in a more effective / individualized ? ?way. Antiangiogenic therapy is
one targeted molecular therapy ? ?arose in the last decade which aims to stop tumor
angiogenesis, ? ?i.e. formation of new blood vessels; hence, minimizing the ? ?tumor’s
volume. However, the corresponding drugs are very ? ?expensive, and in high doses may
have side effects; moreover, ? ?the currently used clinical protocols are ? ?determined
empirically. Consequently, this problem can be seen ? ?as a double optimal control
problem: on the one hand, the aim ? ?is to minimize the tumor’s volume by a model-based
control ? ?algorithm, but it is also crucial to inject the corresponding ? ?inhibitor (drug) in an
optimal way (minimizing costs). Due to ? ?the heterogeneous nature of the patients by a
recently gained ? ?ERC StG grant of the European Union we try to develop a ? ?novel
concept: taming cancer. Beside creating a more realistic ? ?tumor growth mathematical
model, we would like to decrease the ? ?injection sampling time of inhibitors that
combined with a ? ?robust control method can control the tumor volume artificially and ? ?in
this taming it. As a result, it would be even possible ? ?living with the tumor in a controlled
way.
? Short Bio ?: Prof. Dr. habil. Levente Kovács received ? ?his PhD from the Budapest
University of Technology and ? ?Economics in 2008, currently full professor and vice
rector of ? ?education at Obuda University. His fields of interest are modern ? ?control theory
and physiological controls – within these ? ?subjects, he has published more than 350
articles in ? ?international journals and refereed international conference ? ?papers,
accumulating an impact factor over 59 and h-index ? ?16.
From 2012 he is IEEE EMBS and IEEE SMC Society member and ? ?IEEE CSS Society
member from 2013. At IEEE Hungary Section ? ?level Dr. Kovács is the chair of it from
2017. Since 2015 he ? ?acts as chair of the IEEE SMC Hungary Chapter, while in 2018 ? ?he
founded and is chair of the IEEE CSS Hungary Chapter. He is ? ?member of the IFAC TC
8.2 “Biological and Medical Systems” form ? ?2010, member of the IFAC TC 9.4 “Control
Education” from 2017, ? ?and member of the Hungarian Diabetes Association from 2010
as well. ?